Literature DB >> 28468760

Neuroblastoma.

Jason Shohet1,2, Jennifer Foster3,4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28468760     DOI： 10.1136/bmj.j1863

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  19 in total

1.  P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Authors:  Zhongyan Hua; Yue Zhan; Simeng Zhang; Yudi Dong; Min Jiang; Fei Tan; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Apoptosis       Date:  2018-08       Impact factor: 4.677

2.  Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.

Authors:  Tomomasa Hiramatsu; Jyoji Yoshizawa; Kazuaki Miyaguni; Tetsuro Sugihara; Atsushi Harada; Sayuri Kaji; Goki Uchida; Daisuke Kanamori; Yuji Baba; Shuichi Ashizuka; Takao Ohki
Journal:  Pediatr Surg Int       Date:  2018-02-08       Impact factor: 1.827

3.  Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.

Authors:  Thinh H Nguyen; Balakrishna Koneru; Sung-Jen Wei; Wan Hsi Chen; Monish Ram Makena; Eduardo Urias; Min H Kang; C Patrick Reynolds
Journal:  Mol Cancer Ther       Date:  2019-09-04       Impact factor: 6.009

4.  Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells.

Authors:  Jenna L Gordon; Melissa M Reynolds; Mark A Brown
Journal:  Vet Sci       Date:  2020-04-23

5.  Upregulation of MAPK10, TUBB2B and RASL11B may contribute to the development of neuroblastoma.

Authors:  Jiangtao Liu; Yulin Li
Journal:  Mol Med Rep       Date:  2019-08-20       Impact factor: 2.952

6.  CHL1 and NrCAM are Primarily Expressed in Low Grade Pediatric Neuroblastoma.

Authors:  Robin Wachowiak; Steffi Mayer; Anne Suttkus; Illya Martynov; Martin Lacher; Nathaniel Melling; Jakob R Izbicki; Michael Tachezy
Journal:  Open Med (Wars)       Date:  2019-12-31

7.  The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness.

Authors:  Liselot M Mus; Irina Lambertz; Shana Claeys; Candy Kumps; Wouter Van Loocke; Christophe Van Neste; Ganesh Umapathy; Marica Vaapil; Christoph Bartenhagen; Genevieve Laureys; Olivier De Wever; Daniel Bexell; Matthias Fischer; Bengt Hallberg; Johannes Schulte; Bram De Wilde; Kaat Durinck; Geertrui Denecker; Katleen De Preter; Frank Speleman
Journal:  Sci Rep       Date:  2020-01-14       Impact factor: 4.379

Review 8.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

9.  LINC00673 rs11655237 C>T confers neuroblastoma susceptibility in Chinese population.

Authors:  Zhuorong Zhang; Yitian Chang; Wei Jia; Jiao Zhang; Ruizhong Zhang; Jinhong Zhu; Tianyou Yang; Huimin Xia; Yan Zou; Jing He
Journal:  Biosci Rep       Date:  2018-02-08       Impact factor: 3.840

10.  Epigenetic deregulation of GATA3 in neuroblastoma is associated with increased GATA3 protein expression and with poor outcomes.

Authors:  Bader Almutairi; Jessica Charlet; Anthony R Dallosso; Marianna Szemes; Heather C Etchevers; Karim T A Malik; Keith W Brown
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.